GREENFIELD, Ind., Jan.
22, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a
division of Eli Lilly and Company (NYSE: LLY), announced the
approval of Credelio® (lotilaner). Credelio is a
new monthly oral tick and flea treatment that is easy on dogs, but
tough on ticks and fleas. This new tick and flea option for dogs
contains the patented active ingredient lotilaner, which targets
the nervous system receptors of ticks and fleas, not
dogs.1
Credelio is a small, tasty2 chewable tablet approved
for puppies and dogs eight weeks of age and older and 4.4 pounds
and greater. Credelio protects against ticks of common concern
across the U.S.: lone star tick (Amblyomma americanum),
American dog tick (Dermacentor variabilis), black-legged
tick (Ixodes scapularis) and brown dog tick
(Rhipicephalus sanguineus), as well as fleas
(Ctenocephalides felis).
"When choosing pet medications, veterinarians and pet owners are
most concerned with safety for the pet as well as efficacy of the
product. Lotilaner, the active ingredient in Credelio, was selected
from hundreds of candidate molecules with this in mind," said
Tony Rumschlag, DVM, Director,
Regional Consulting, Elanco Animal Health. "This new tasty chewable
is fast-acting and effective against ticks and fleas, while being
easy on dogs and puppies. Credelio rounds out the Elanco portfolio
of companion animal parasiticides to allow a very broad set of
options to best meet the needs of pet owners and their pets."
Easy on Dogs
In a field study, 100 percent of
Credelio tablets were administered successfully and dogs accepted
94 percent of them when offered by hand, in an empty bowl, or with
food.2 Credelio is also well accepted by a broad range
of dog breeds, including toy dogs such as Chihuahuas and Yorkshire
terriers.2-5 Further, Credelio offers the reassurance of
a product that is suitable for puppies as young as eight weeks of
age.
Tough on Ticks and Fleas
Credelio's active
ingredient—lotilaner—circulates in the dog's blood stream,
targeting the receptors of ticks and fleas when they bite the dog.
In clinical studies, Credelio killed 100 percent of fleas within 12
hours for the entire month.6 Credelio starts to kill
ticks and fleas in just 4 hours6,7. This fast initial
onset of action provides rapid relief from existing ticks.
Credelio's sustained speed-of-kill throughout the dosing period
provides protection from newly-acquired ticks. Credelio works fast
because it is absorbed rapidly and achieves peak plasma levels
quickly. When given with food, Credelio reaches peak blood levels
within 2 hours of dosing.8
As a global leader in the animal health industry, Elanco
supports veterinarians with a wide range of parasiticide solutions.
"The introduction of Credelio expands our portfolio even further
with a once-a-month, oral tick and flea product that supports
Elanco's commitment to helping pets live longer, healthier,
higher-quality lives," said Cathy
Martin, Director of U.S. Companion Animal Marketing.
Credelio will be available in four tablet strengths for dogs and
is approved for puppies and dogs from eight weeks of age and older
and 4.4 pounds and greater.
Visit Credelio.com for more information.
Indications
Credelio kills adult fleas and is
indicated for the treatment of flea infestations
(Ctenocephalides felis) and the treatment and control of
tick infestations [Amblyomma americanum (lone star tick),
Dermacentor variabilis (American dog tick), Ixodes
scapularis (black-legged tick) and Rhipicephalus
sanguineus (brown dog tick)] for one month in dogs and puppies
8 weeks of age and older, and weighing 4.4 pounds or greater.
Important Safety Information
The safe use of Credelio
in breeding, pregnant, or lactating dogs has not been evaluated.
Use with caution in dogs with a history of seizures. The most
frequently reported adverse reactions are weight loss, elevated
blood urea nitrogen, excessive urination, and diarrhea. See package
insert for full safety information.
About Elanco
Elanco provides comprehensive products
and knowledge services to improve animal health and food-animal
production in more than 70 countries around the world. We value
innovation, both in scientific research and daily operations, and
strive to cultivate a collaborative work environment for more than
6,500 employees worldwide. Together with our customers, we are
committed to raising awareness about global food security, and
celebrating and supporting the human-animal bond. Founded in 1954,
Elanco is a division of Eli Lilly and Company. Our worldwide
headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com
and EnoughMovement.com.
References
1Rufener, L. et al. 2017.
"The novel isoxazoline ectoparasiticide lotilaner
(Credelio®): a noncompetitive antagonist specific to
invertebrates γ-aminobutyric acid-gated chloride channels
(GABACls)." Parasites & Vectors. 10:530.
2Karadzovska, D. et al. 2017. "A randomized,
controlled field study to assess the efficacy and safety of
lotilaner flavored chewable tablets (Credelio®) in
eliminating fleas in client-owned dogs in the USA." Parasites & Vectors. 10:528.
3Cavalleri, D. et al. 2017. "A randomized, blinded,
controlled field study to assess the efficacy and safety of
lotilaner tablets (Credelio®) in controlling fleas in
client-owned dogs in European countries." Parasites &
Vectors. 10:526.
4Cavalleri, D. et al. 2017. "A randomized,
controlled study to assess the efficacy and safety of lotilaner
(Credelio®) in controlling ticks in client-owned dogs in
Europe." Parasites
& Vectors. 10:531.
5Elanco Animal Health. Data on File.
6Cavalleri, D. et al. 2017. "Assessment of the speed
of flea kill of lotilaner (Credelio®) throughout the
month following oral administration to dogs." Parasites &
Vectors. 10:529.
7Murphy, M. et al. 2017. "Laboratory evaluation of
the speed of kill of lotilaner (Credelio®)
against Ixodes ricinus ticks on dogs." Parasites and Vectors.
10:541.
8Toutain C. et al. 2017. "The intravenous and oral
pharmacokinetics of lotilaner in dogs." Parasites &
Vectors. 10:522.
Credelio, Elanco, and the diagonal bar logo are trademarks of
Eli Lilly and Company or its affiliates.
© 2018 Eli Lilly and Company or its affiliates. USCACCRD00055
View original content with
multimedia:http://www.prnewswire.com/news-releases/elanco-animal-health-announces-us-food-and-drug-administration-fda-approval-of-credelio-lotilaner-to-treat-and-protect-against-ticks-and-fleas-300585725.html
SOURCE Elanco Animal Health